Federal Register Notice: FDA has determined the regulatory review period for Bayer Animal Health’s Veraflox is 3,285 days for extending a patent which claims the animal drug product. Veraflox (pradofloxacin) is indicated for treatment of skin infections in cats caused by susceptible strains of Pasteurella multocide, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis, and
Staphylococcus pseudintermedius. To view this notice, click here.
